.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moody's upgrade, below are the headlines from my E*TRADE acct:
6:46 PM ET Moody's Cites Continued Expected Improvement In Sirius' Oper Results
6:45 PM ET Moody's Boosts Sirius XM's PDR To B3 From Caa3
6:45 PM ET Moody's Boosts Sirius XM's SGL Rtg To SGL-2 From SGL-3
6:44 PM ET Moody's: About $2.3B Of Sirius XM Debt Instruments Affected
6:44 PM ET Moody's Boosts Sirius XM's CFR To Caa1 From Ca
GL.
BTIM looks like a good mid-long term play, IMO. Lots of potential with their stem-cell tech.
GL.
In the .89s after-hours...
GLTA.
Cordex Retains WBB Securities to Explore Strategic Options
LA JOLLA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has retained WBB Securities LLC to help the company explore strategic alternatives to enhance shareholder value.
Cordex has developed a portfolio of diagnostic and therapeutic drug candidates, two of which are in late stages of clinical development: ATPace™ has an approved SPA to enter a pivotal Phase 2b/3 clinical trial for the treatment of a common heart arrhythmia called paroxysmal supraventricular tachycardia. Cordex believes that ATPace™ is a more reliable and superior product than existing therapies because of its unique ability to recruit the vagus nerve.
As a diagnostic test for syncope, ATPace™ is ready for a Phase 3 clinical trial. Diagnosis of syncope is a major unmet medical need. Cordex believes this product may impact the syncope market much the same way adenosine-based pharmaceutical stress agents expanded the myocardial perfusion imaging market.
Another of Cordex's ATP-based product, ATPotent™, targets male factor infertility. Pre-clinical data have demonstrated the ability of ATPotent™ to improve sperm motility and increase conception rates. ATPotent™ can be developed either as a therapeutic agent (in IUI or IVF procedures) or as a medical device (a sperm wash). Other ATP-based products target the P2 receptors in the lung and the eye for the treatment of COPD and chronic cough and glaucoma, respectively.
A Cordex program at the Phase 2 proof-of-concept clinical trial stage is a nitric oxide-based product for the treatment of heart failure.
"We believe that we can best serve the interests of all our shareholders by exploring every possible alternative to enhance shareholder value," stated Cordex's CEO Shepard Goldberg.
About Cordex Pharma, Inc.
Cordex is focused on hospital-based therapies based upon the emerging new pharmacological mechanisms of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.
About WBB Securities LLC.
Headquartered in San Diego, WBB is an independent broker/dealer specializing in biotechnology, specialty pharma, and medical devices investment banking and research. For further information regarding WBB or to contact the firm, please visit www.wbbsec.com.
Steve Brozak
President
WBB Securities LLC
125 Elm Street
Westfield, NJ 07090
Contact: Mark Molowa
(908) 518-7610
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding the expected results of the use of ATPace(TM) and enhancing shareholder value. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the data derived from the trials may not be sufficient to support marketing or approval of the products, the market may not be as anticipated and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
iBOX updated...
Theratechnologies Reports That the FDA Will Reschedule for Administrative Reasons the Advisory Committee Meeting to Review Tesamorelin's NDA
MONTREAL, QUEBEC, CANADA--(Marketwire - Jan. 25, 2010) - Theratechnologies (TSX:TH - News) today announced that the U.S. Food and Drug Administration ("FDA") will reschedule its meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to review Theratechnologies' New Drug Application ("NDA") for tesamorelin. Originally scheduled for Wednesday, February 24, 2010, the meeting will be rescheduled due to an administrative delay at the FDA. The FDA informed Theratechnologies that this delay is entirely procedural and is not related to the tesamorelin NDA. A new meeting date will be announced shortly in the Federal Register.
Theratechnologies submitted an NDA to the FDA on May 29, 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA filed the NDA on August 12, 2009, which initiated a substantive review of the application. The Prescription Drug User Fee Act ("PDUFA") date, which is the target date for the FDA to complete its review of tesamorelin's NDA, is March 29, 2010.
About HIV-Associated Lipodystrophy
Several factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients.
About Theratechnologies
Theratechnologies (TSX:TH - News) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.
In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.
With a New Drug Application filed with the U.S. authorities in May 2009, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions.
No problem... Their drug is for a $600M market. ~60.4M shares outstanding, could hit $10 w/ an advisory committee vote in favor of approval, IMO.
GL.
PDUFA Date for tesamorelin is March 29, 2010.
Corporate Presentation PDF
http://theratech.com/docs/en/corpo/2010-01-04_TH_PresentationCorpo.pdf
They have an innovative drug, but some cash problems. If I read the sec filings correctly, the patents expire on their depression drug, so if they want the patents extended, they'll have to find some cash and do some quick clinical trials.
They recently settled w/ one of their creditors, but I'm not sure if there are more creditors remaining or not.
Thanks!
Well, they have a lot of shorts, and it could possibly have a short squeeze if it can break $1, IMO.=
GLTA.
As of right now my biggest holding is not a biotech -- SIRI. I plan on selling it in the next few days and re-entering DDSS, GNVC, BNVI, and ANX.
Also, I am slowly accumulating shares of TTRX.OB -- but it's a very risky, longer-term play.
GL.
Initiating Nile Therapeutics - Outperform
We are initiating coverage of Nile Therapeutics (NasdaqCM: NLTX) with an Outperform rating and a near-term price target of $2.50 per share. Nile is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF).
This is a highly coveted area by large-cap pharmaceutical companies. The opportunity is wide-open, and a significant breakthrough product could capture blockbuster sales a few years after launch. For example, Johnson & Johnson’s Natrecor (nesiritide) was annualizing at $400 million in sales -- and on its way toward a billion -- in 2004 prior to the safety issues that still today dramatically limit the product's uptake.
Heart Failure Treatment at Present
Standard of care is a mixture of vasodilators, diuretics and inotropic agents, almost all available as generics, with no real advancement in over a decade.
In the U.S., approximately 5.5 million people (~2% of the population) suffer from heart failure (HF). The incidence is even higher for patients above the age of 65, where approximately 6% to 10% of the population is at risk. There are an estimated 650,000 new cases diagnosed annually. Treatment of heart failure generates annual costs of approximately $35 billion, of which approximately $3 billion is spent on drugs and $19 billion is spent in the acute hospital setting. Each year, HF is responsible for over 1.2 million hospitalizations. For Americans over the age of 65, ADHF is the most frequent cause of hospital admission.
In the past, the goal was simple: reduce cardiac filling pressure and effectively and safely increase diuresis; and do all this with a low risk of hypotension. Once the patient had been stabilized, discharge them. Still, the average length of hospital stay is 4.3 days. However, subsequent to a discharge, the average time to re-admission is only 3 months and mortality is high. In fact, 50% of patients discharged with a primary or secondary code of ADHF will require re-hospitalization during the following 9 months. A third will be dead within the year.
However, over the past several years, significant effort by the medical research community has been put forth to better understand the cardio-renal link between heart failure and mortality. Among patients hospitalized for ADHF, worsening renal function is predictive of adverse cardiovascular outcomes. In fact, the single strongest predictor of in-hospital mortality in patients admitted with ADHF is elevated blood urea nitrogen (BUN).
The Future of Treating Heart Failure
Therefore, the ideal pharmaceutical product is one that can safely and effectively reduce cardiac filling pressure, increase diuresis, and also preserve kidney function -- all with a low risk of hypotension. Nile’s CD-NP was rationally designed by scientists at the Mayo Clinic’s cardio-renal research labs to do just this.
The drug is a combination of two natriuretic peptides, CNP and DNP. The scientists at the Mayo Clinic developed the drug combining the n-terminus of the CNP molecule, preserving its favorable venodilating and hemodynamic properties, with the c-terminus of the DNP molecule, preserving its potent direct renal activity. Preclinical data demonstrates the drug has both natriuretic and diuretic properties. Prior phase I and phase II data has been highly encouraging.
Management is currently conducting a second phase II program with top-line data expected in March 2010. With positive data in hand, we believe management will seek to partner the drug prior to the initiation of a phase IIb efficacy program later in 2010 or in 2011.
Positive on CD-NP
We think if Nile can demonstrate the effectiveness of CD-NP in the planned phase IIb, management can fetch $300 million on a takeover in 2011 or 2012. However, shareholders may not have to wait that long to start to see the stock move higher. Full data from the current phase II program is expected around the middle of this year, and we fully expect management to secure funding from a partnership shortly after that time. We could be looking at an upfront payment plus a potential takeover milestone in 2011.
With a market capitalization of only $30 million, Nile Therapeutics shares are significantly under-valued. Recently the stock has languished, most likely due to a lack of meaningful news-flow over the past few months or the knowledge on Wall Street that past drugs in this space have failed (see: J&J’s Natrecor, Merck’s rolofylline). But we have confidence in the ongoing phase II program. We believe with positive data in hand, the company is worth at least $80 to 100 million.
Taking the mid-range at $90 million, and then backing out the $20 million most likely required to fund the phase IIb program, we arrive at a value of $70 million for Nile Therapeutics. This equates to a price of $2.50 per share.
For additional information please see our full initiation report on Zacks.com, or contact your Zacks Research Sales Representative.
NILE THERAPEUTICS INC (NLTX): Read the Full Research Report
Zacks Investment Research
Called the company several times today... No answer.
GLTA.
Thanks... I would've bought back in today but all my cash is tied up right now. :/
GLTA.
GNVC is presenting a great buying opportunity today, in my opinion.
GLTA.
Repros Receives Guidance from FDA Regarding Continued Development of Androxal® in Hypogonadal Men
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company and its consultants participated in a teleconference with the Division of Reproductive and Urologic Products of the FDA on January 25, 2010. The primary purpose of the meeting was to gain a better understanding of the FDA’s position regarding the use of Repros’ oral Androxal® product in the treatment of men with secondary hypogonadism wishing to preserve their fertility. The Company’s data supports the notion that the negative feedback of exogenous testosterone administered by any route suppresses the hypothalamic–pituitary axis and hence spermatogenesis.
The discussion with the FDA focused on two issues. Firstly, the FDA requested that the Company propose a label that better defines the population of individuals for whom Repros believes will benefit from the use of Androxal. Secondly, the FDA requested the Company conduct a literature review of the incidence of infertility associated with the use of exogenous testosterone as supportive of the Company’s data. The FDA requested that the Company provide such information and if the FDA finds the submission appropriate no additional clarifying meeting regarding the indication for Androxal may be required. During the course of the meeting Repros noted that if the FDA concurred with the indication proposed by the Company, Repros would like to request a special protocol assessment (SPA). The FDA responded that the issues noted above should be resolved first before undertaking a protocol review.
On the call for Repros were Dr. Jean Fourcroy MD, Repros Board member and former medical officer at the division of Reproductive and Urologic Products at the FDA (CDER), Dr. Andre T. Guay MD, Center for Sexual Function (Endocrinology), Lahey Clinic (Dr. Guay has authored numerous publications on the use of Clomid in the treatment of secondary hypogonadism), Dr. Jed Kaminetsky MD, Department of Urology, New York University Medical Center, a practicing urologist in the metropolitan area of New York focusing on reproductive disorders and a principal investigator in a Repros study, Dr. Ronald Wiehle, VP of R&D at Repros and Joseph Podolski, President and CEO. Repros and its consultants believe that they can clearly define the intended patient population who will benefit from the use of Androxal and provide the FDA with existing scientific citations that support the notion that exogenous testosterone administration impairs male fertility.
In a study previously completed by Repros, blinded Androxal 12.5mg and 25mg were compared to open label Androgel used per manufacturers recommendations and blinded placebo in hypogonadal men that met the criteria of secondary hypogonadism (T<300 ng/dl, LH<15mIU/ml). In this balanced 200 patient trial, at six months of exposure, exogenous testosterone (Androgel) suppressed both luteinizing hormone (LH) and follicle stimulating hormone (FSH) in a statistically significant manner. Each of these hormones was suppressed by greater than 60% compared to baseline (p value < 0.0001). By contrast Androxal improved both LH and FSH in this population in a dose dependent manner with the 25 mg dose of Androxal showing a median change of greater than 90% for both important reproductive related hormones (p value <0.0001). In a subsequent study Repros correlated the reductions of FSH seen with exogenous testosterone with suppression of sperm counts. In this second small trial, 2 of 5 subjects on exogenous testosterone had no detectable sperm at 3 and 6 months and an additional subject had less than 5 million sperm per milliliter of semen. Four of five men at 3 months and three of five at 6 months were oligospermic (<20 million sperm per milliliter) during the trial. By contrast the six men on Androxal exhibited sperm concentrations with a mean of >150 million sperm per milliliter, with all six of the subjects exhibiting concentrations well above the generally accepted level of fertility of 20 million sperm per milliliter. The difference between the Androxal group and the Testim group achieved statistical significance (p<0.01), even though this was a small pilot study. As expected, Androxal improved FSH, the hormonal driver of spermatogenesis and Testim suppressed FSH as evidenced by the suppression of spermatogenesis. The difference in FSH between the two treatment groups also achieved statistical significance at months three and six (p<0.02).
Supportive of Repros’ data is a study reported in the Journal of Andrology, Vol. 22 No. 6, November/December 2001 entitled “Daily Testosterone and Gonadotropin Levels are Similar in Azoospermic and Nonazoospermic Normal Men Administered Weekly Testosterone: Implications for Male Contraceptive Development”, J.K. Amory et al. In that article it was noted that after 6 months of treatment of normal men with an exogenous testosterone dose (50 mg weekly injection) that maintained morning testosterone levels within the normal range, sperm counts were reduced by 60%. In the instance of a dose that produced morning testosterone levels slightly above the normal range (100 mg weekly injection) azoospermia (no sperm) was induced in roughly 50% of the normal subjects.
Repros also proposed the use of Androxal in a pulsed fashion to reverse hypogonadism induced by either drugs or physical condition in younger men. Though the FDA understood this application the Agency chose to focus the discussion on the larger indication.
Joseph S. Podolski, President and CEO of Repros, noted, “We are encouraged by the open and constructive dialogue exhibited by the FDA during the teleconference. We look forward to providing the FDA with the requested materials in the next few weeks.” The FDA noted once they receive the Company’s materials that Repros could expect a timely response.
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to maintain its listing on the NASDAQ Capital Market, raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, successfully defend itself against the class action complaints, whether clinical trials of Proellex® may be resumed, whether any safe and effective dose for Proellex can be determined, whether a clear clinical path for Androxal can be determined and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company's website at http://www.reprosrx.com.
TTRX.OB - 0.04 - (Tetragenex Pharmaceuticals, Inc.):
Biotech w/ ~15.9M shares outstanding. Promising depression drug (nemifitide. Filed for Ch.11 in 2009, but the court threw it out. A few days ago, the company filed a form w/ the SEC stating that they are settling w/ a creditor.
Link to most recent SEC Filing: http://sec.gov/Archives/edgar/data/1362659/000109690610000064/0001096906-10-000064-index.htm
Company website: http://www.tetragenex.com/
Do your OWN DD before investing! You are responsible for your own trades!
GLTA.
About Nemifitide (from co. website):
Early pre-clinical animal studies demonstrated the powerful potential of nemifitide as a treatment for patients suffering from depression. These pre-clinical results have been confirmed by the clinical studies that we have conducted on over 400 individuals who have received nemifitide to date.
In double-blinded placebo controlled trials, nemifitide has demonstrated strong eveidence of efficacy in depressed patients. The clinical profile included a more robust and rapid onset of action with long duration and minimal adverse side effects. Extensive testing over the last ten years has demonstrated that nemifitide has distinct advantages over other drugs currently marketed to treat depression.
Rapid onset of action and symptomatic relief.The initial effects of nemifitide are observable in the first three to five days of treatment. Peak effects occur within one to two weeks, versus four to eight weeks for currently available antidepressants. Nemifitide may be used for severely depressed patients who require rapid symptomatic relief, as effectiveness can be clinically measured within 3-5 days of initiating treatment.
Little or no side effects. Nemifitide, to date, has been administered to over 400 patients and volunteers with only one patient discontinuing treatment due to side effects. This is in marked contrast to all other currently available antidepressants, which often cause short and long-term side effects frequently resulting in the premature discontinuation of treatment.
Many patients experience complete symptomatic relief. Many patients who respond to nemifitide enter into complete remission from their depression, as opposed to simply experiencing some improvement in their condition.
Potential to treat severely refractory patients. Preliminary results from an open-label pilot study (a clinical trial without the use of a placebo) in severely refractory patients(patients who have not responded to several classes of antidepressant therapy over long periods of time) have shown a response rate of over 40%. This generated a considerable amount of interest in the scientific community and, we believe, this could give nemifitide a novel role in treating this debilitating illness. It is estimated that approximately 5% to 10% of patients suffering from major depression have the refractory form of the illness.
Freedom from regular daily treatment. Because nemifitide is administered via ten to fifteen subcutaneous or needleless injections over a two to three week period, and has a long duration of effective action, it allows for intermittent clinical treatment (every four to six months) versus the chronic daily dosing required with most existing antidepressant medications. This may result in dramatically improved patient complience.
Potential to treat other CNS disorders. In addition to treating major depression, nemifitide and other patented peptides we intend to develop may be effective in the treatment of mild depression, anxiety disorders, as well as other central nervous system disorders such as anorexia, bulimia, panic disorder and post-traumatic stress disorder.
Potential for alternative forms of administration. Preliminary evidence indicates that nemifitide may be administered through needleless injections. We also intend to explore other forms of delivery, including a transdermal patch (through the skin by way of a patch) as well as nasal inhilation.
Little or no potential for adverse reactions with other drugs. Based on studies conducted to date, nemifitide is not expected to show significant drug-drug interaction in human beings. This is especially beneficial in the treatment in the geriatric population and cardiac patients with depression.
We believe nemifitide has the potential to revolutionize the antidepressant market. Antidepressant sales constitute the largest segment of the CNS market, approximately 24%. In 2004, global sales of antidepressant agents exceeded $15 billion. Based on the sales of other antidepressants, we believe that nemifitide, properly marketed, has the potential to become the treatment of choice for depression and to capture a substantial portion of the worldwide market after commercialization.
New SEC Filing on Jan. 20th!!!
http://sec.gov/Archives/edgar/data/1362659/000109690610000064/0001096906-10-000064-index.htm
GLTA.
Wow. Just saw the movement today... Amazing! Maybe we'll be getting news soon?
Fairly good results, IMO. But, it's still in early stages of testing. I honestly don't see much upside for a while. Anything can happen in Phase 2/Phase 3 trials. If you would be holding them for several years, it could possibly be a good long-term play though, IMO.
GL!
Thanks for the post! Was in SPPI a while back before they got the CRL. Might be worth buying back into soon, imo.
GLTA.
Did some DD on this one, looks good. Picked some up in the .086s!
GLTA.
Already have some pre-market action on PARD.
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=PARD&mkttype=pre
Transition Therapeutics Announces Results of a Phase 2 Study of TT-223 in Type 2 Diabetes Patients
TORONTO, Jan. 25, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH - News) (Nasdaq:TTHI - News) today announced the results from a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. Patients who received the highest daily dose of TT-223 for 12 weeks and completed the entire study without adjusting their diabetes therapies experienced a statistically significant reduction in HbA1c of 1.13%, 6 months after completing TT-223. Patients who had received placebo treatment experienced a 0.22% HbA1c reduction 6 months post-treatment. HbA1c is a reflection of a person's average glucose level and is used by doctors as a measure of glucose management. Post prandial and AUC (area under the curve) glucose showed improvement versus placebo but not against baseline at 3 and 6 months post-treatment, while fasting blood glucose and mixed meal tolerance insulin parameter tests did not show improvement. No detectable changes in weight were observed.
There were no treatment-related serious adverse events. The most common adverse event was nausea, which was generally mild to moderate and decreased in frequency and severity over the treatment period.
"These data are very encouraging and supports the gastrin based approach. The progressive reduction in HbA1c levels six months after completion of treatment suggests potential disease-modifying properties of gastrin based therapies and differentiates them from other diabetes treatments," said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.
Study Design
The study was a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of once-daily subcutaneous injections of TT-223. The study enrolled type 2 diabetes patients who were unable to achieve adequate glucose control. The study consisted of two main stages, a 12 week treatment period and a 6 month follow-up period. Patients continued their current background diabetes therapy through both stages.
The once-daily dose of TT-223 was titrated as tolerated to the maximum dose during the first three weeks, and patients remained on the highest tolerated dose for the remaining nine weeks of the treatment period. After the completion of the treatment period, patients were followed for an additional six months to monitor the safety and efficacy of the TT-223 therapy.
About Gastrin-Based Therapies
Transition and Eli Lilly and Company (NYSE:LLY - News) have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize gastrin based therapies. Gastrin based therapies are an emerging class of potential disease-modifying therapies for patients with diabetes, and have been shown to provide sustained improvement in glycemic control in preclinical models and early clinical studies. Sustained improvement in glycemic control is a key goal for patients with diabetes in order to alleviate the symptoms of hyperglycemia and to prevent diabetic complications, and improving their overall quality of life.
About Transition
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the Ontario Securities Commission, United States Securities and Exchange Commission or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials the potential disease-modifying properties of gastrin based therapies, if any. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions and the SEC.
For further information on Transition, visit www.transitiontherapeutics.com
Anywhere between $3.50-$5.00. If enough shorts jump in to cover, we could see mid-high 6s, imo.
GL.
Great news! Should really pop on Monday, especially with shorts covering.
GL!
Should be getting 510k clearance any day now, imo.
GLTA.
IMO, upon FDA clearance, GTF could get up to $2+.
Very promising technology that Cytomedix has, and once they get clearance, people will find out about it, and it'll fly, IMO.
P.S. If there are any more boards you'd like to be assistant on, just let me know!
Have a great weekend as well!
Picked up some PARD after hours for $2.63.
GLTY.
Out GNVC @ $3.0305...
GNVC blowing up!
Possibly... But Saito was wrong on VION.OB and GETA.OB. Only time I've seen him right is w/ SNTS.
The thing that scares me about HNAB is the fact that they want to submit an NDA based on a Phase 2 trial, VION tried the same thing, and failed, ended up filing for Ch. 11.
However, HNAB could be a 50%-100%+ gainer in the next few months, so it'd probably be good for a trade or two!
GL!
Congrats! Great call!
Huge news, in my opinion. Thanks for posting! Will be stickied...
No problem!
As for the new Camaro's - Nope.. I wish
GL.
Thanks for the post and for bringing PARD to my attention!
GL.
Something else I just read about PARD -- PARD is presenting data at the ASCO Gastrointestinal Cancers conf. on Saturday, could move them up quite a bit, imo.
GL.